Physician profile
Willard W Beard
NPI 1598916330
$7,658.22
in general payments reported to CMS, 2019-2025
30 companies · $2,112 in 2025
The $2,112 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,191 · 2022: $1,316 · 2023: $1,387 · 2024: $1,652 · 2025: $2,112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,150.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,083.95 | 2021-2025 | |
| Novo Nordisk INC | $1,057.89 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $732.71 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Takeda Pharmaceuticals U.S.A., INC. | $592.43 | 2021-2025 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $559.32 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $403.62 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $367.22 | 2021-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $264.21 | 2021-2025 | Rexulti |
| Pfizer INC. | $179.78 | 2021-2025 | |
| Abbott Laboratories | $175.93 | 2021-2025 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $151.82 | 2021-2025 | Zoryve, Livalo |
| Biohaven Pharmaceuticals, INC. | $120.46 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.24 | 2021-2025 | Xifaxan |
| Lundbeck LLC | $84.23 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $83.38 | 2024-2025 | Caplyta |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $80.98 | 2021-2025 | Otezla, Repatha, Repatha |
| Axsome Therapeutics, INC. | $74.07 | 2023-2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $73.62 | 2024-2025 | |
| Exact Sciences Corporation | $69.37 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $57.56 | 2022 | |
| Ardelyx, INC. | $48.82 | 2025 | Ibsrela |
| Idorsia Pharmaceuticals US INC | $47.47 | 2022-2024 | Quviviq |
| Amarin Pharma, INC. | $46.44 | 2021 | |
| Astellas Pharma US INC | $44.06 | 2022-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $34.13 | 2021 | |
| Currax Pharmaceuticals LLC | $30.86 | 2024-2025 | Contrave, Onzetra Xsail |
| Mylan Specialty L.P. | $28.15 | 2022-2023 | Yupelri |
| Sanofi-Aventis U.S. LLC | $27.63 | 2021-2022 | |
| Dexcom, INC. | $19.64 | 2022 | |
| Bausch Health US, LLC | $19.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Willard Beard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.